Rafeh Naqash: The Role of STK11/KRAS in Early Stage NSCLC
Rafeh Naqash, Assistant Professor at OU Health Stephenson Cancer Center and 2025 Yvonne ‘Mentorship’ Award Winner, shared a post on X about a recent article he and his colleagues co-authored published in Translational Lung Cancer Research:
“Nice summary here on the role of STK11/KRAS in early stage NSCLC from our group led by Alessio Cortellini on what you need to know from the TME standpoint”
Title: KRAS and STK11 co-mutations in resectable non-small cell lung cancer: enduring prognostic value and impaired immunotherapy response
Authors: Luisana Sisca, Priscilla Cascetta, Ayesha Aijaz, Chiara Catania, Francesco Facchinetti, Abdul Rafeh Naqash, Biagio Ricciuti, Alessio Cortellini.
You can read the Full Article on the Translational Lung Cancer Research.
More posts featuring Rafeh Naqash on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023